Messer T

Danuvius Klinik GmbH, Technische Universität München , ,

2 papers

ArticleKetamine

Top-line Results from ESCAPE-LTE: An Open-Label Extension Study to Assess Long-term Safety of Esketamine Nasal Spray in Treatment Resistant Depression

Godinov Y, Fu D, von Holt C +10

Europe PMC2025
ArticleKetamine

Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomised, phase IIIb clinical trial

Reif A, Anıl Yağcıoğlu A, Luts A +10

Europe PMC2023